Skip to main content
Clinical Trials/ACTRN12611000646943
ACTRN12611000646943
Recruiting
Phase 4

A multi-center, prospective, randomised controlled trial comparing the efficacy and safety of PRODISC-C (Registered Trade Mark) implant to anterior cervical discectomy and fusion (ACDF) surgery, in the treatment of symptomatic cervical disc disease (SCDD)

Synthes Asia Pacific0 sites300 target enrollmentJune 23, 2011

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Symptomatic cervical disc disease (SCDD)
Sponsor
Synthes Asia Pacific
Enrollment
300
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 23, 2011
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Synthes Asia Pacific

Eligibility Criteria

Inclusion Criteria

  • 1\.Subjects with symptomatic cervical disc disease (SCDD) in only one vertebral level between C3\-C7 defined as:
  • Neck or arm (radicular) pain; and/or a functional / neurological deficit with at least one of the following conditions confirmed by imaging (Computed Tomography scans, Magnetic Resonance Imagings or X\-rays)
  • \-Herniated nucleus pulposus
  • \-Spondylosis (defined by the presence of osteophytes)
  • \-Loss of disc height
  • 2\.Unresponsive to non\-operative treatment for approximately six weeks or has the presence of progressive symptoms or signs of nerve root compression in the face of conservative treatment.
  • 3\.Neck Disability Index (NDI) score greater than or equal to 15/50 (30%) (Considered moderate disability).

Exclusion Criteria

  • 1\.More than one vertebral level requiring treatment (showing marked changes at a second level)
  • Marked cervical instability on resting lateral or flexion/extension radiographs:
  • a.translation greater than 3 mm and/or
  • b.greater than 11 degrees of rotational difference to that of either adjacent level .
  • 2\.Radiographic confirmation of severe facet joint disease or degeneration.
  • 3\.Known allergy to cobalt, chromium, molybdenum, titanium or polyethylene.
  • Clinically compromised vertebral bodies at the affected level(s) due to current or past trauma, e.g., by the radiographic appearance of fracture callus, malunion or nonunion.
  • 4\.Severe spondylosis at the level to be treated as characterized by any of the following:
  • \- Bridging osteophytes;
  • \- A loss of disc height greater than 70%

Outcomes

Primary Outcomes

Not specified

Similar Trials